Compare Marvell Technology Inc (MRVL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs TG Therapeutics Inc — how do they compare? Marvell Technology Inc trades at $211.8 (market cap $171.11B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Marvell Technology Inc is far larger — about 20.7× TG Therapeutics Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MRVL | TGTX | |
|---|---|---|
Market Cap | $171.11B | $8.26B |
Sector | Technology | Health |
52-Week High | $316.43 | $59.06 |
52-Week Low | $62.31 | $26.39 |
Enterprise Value | $172.55B | $8.50B |
Dividend Yield | 0.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $207.96, up 10.22% on the day, reflecting strong momentum amid AI-driven chip stock enthusiasm. The stock shows bearish technical signals but benefits from consistent earnings beats and robust analyst support with an 82% buy rating. Recent news highlights its 251% surge in H1 2026 and strategic positioning in AI infrastructure, though volatility persists due to sector-wide capex concerns. Fundamentals reveal high valuation multiples (P/E 66.99) against negative net income, offset by solid gross margins (51.5%) and projected revenue growth to $8.7B in 2026.
Outlook: MRVL offers growth exposure to AI networking and custom silicon, with a consensus price target of $275.68 implying 32% upside. Risks include execution challenges in scaling profitability, debt levels ($3.93B long-term), and sensitivity to AI spending cycles. The stock's premium valuation demands flawless execution to justify current levels amid competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
